CANTON, Mass., June 2 /PRNewswire-FirstCall/ -- Avitar, Inc. (Amex: - ) today announced that David Greaves has been appointed Vice President of Sales. Mr. Greaves most recently held the position of Vice President - U.S. Sales for Heroix Corporation of Newton, MA, a systems software company which provides monitoring and management of IT infrastructure. Previously, Mr. Greaves held similar positions with Fortel Software of Fremont, California, and Cognimed LLC of Lexington, MA.
"We are very pleased to have a person with David's senior sales management experience join our management team," said Peter P. Phildius, Chairman & CEO. "As previously announced, our capital raising efforts are allowing us to begin to implement our revenue growth strategy as we add the necessary resources to penetrate the $1.5 billion drugs-of-abuse testing market. David will oversee the redevelopment of our direct sales capability and the expansion of the relationships with our distribution channel partners in order to execute our business plan."
ABOUT AVITAR
Avitar, Inc. develops, manufactures and markets innovative and proprietary products in the oral fluid diagnostic market, disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Oral fluid diagnostics includes the estimated $1.5 billion drugs-of- abuse testing market, which encompasses the corporate workplace and criminal justice markets. Avitar's products include ORALscreen(TM), the world's first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse. Additionally, Avitar manufactures and markets HYDRASORB(TM) an absorbent topical dressing for moderate to heavy exudating wounds. In the estimated $25 billion in vitro diagnostics market, Avitar is developing diagnostic strategies for disease and clinical testing. Some examples include influenza, diabetes and pregnancy. For more information, see Avitar's website at https://avitarinc.com.
Safe Harbor Statement. This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements
